About Us

image1

Management Team

  • We bring an experienced group of industry veterans for each part of this ecosystem.  
  •  Our management team includes two current CEO of pharma companies that have raised millions of investment capital. 
  • Team education and experience include a  Loyola Medical School educated doctor, Harvard MBA and work experience in senior positions with consulting firms Accenture, KPMG and PriceWaterhouseCoopers.

Problems We Are Solving

  • New ways to raise capital and provide liquidity for life sciences companies through tokenization of future revenues.
  • More cost effective than an Initial Coin Offering (ICO).
  • Bringing liquidity to current long term investors in these life sciences companies. They want to cash out…
  • Prove a model for funding Phase Two clinical trials, the most challenging. 
  • New ways to raise capital and provide liquidity for life sciences companies through tokenization of future revenues.
  • More cost-effective than an Initial Coin Offering (ICO).
  • Bringing liquidity to current long term investors in these life sciences companies. They want to cash out…
  • Prove a model for funding Phase Two clinical trials, the most challenging. 
  • Provide a flexible platform to handle compliance and reliability of digital assets traded on the exchange.
  • Provide easier access to global capital investors in and out. 

Our Solution, A Dedicated Life Sciences Exchange Platform

  •  A crowdfunding platform for investors focused on exceptional growth-stage life sciences companies.
  • A choice of instruments utilizing Smart Contracts to monetize and trade future cash flow.
  • Our two Co-founders are CEO’s of peer group pharma companies we will be recruiting and raising capital for.
  • Investors have a trusted place to invest in their preferred sector and clinical stage.
  • Provide investors with significant capital appreciation over a shorter period of time than commonly found with traditional VC funds.
  • Launching multiple companies on the platform reduces technical and marketing costs to raise capital.

Corporate partners have an interest to leverage our work.

Check back for upcoming news.

Our Cofounders

David Seftel, M.D., M.B.A. (Harvard) CEO, Enable Biosciences, CMO, Life Sciences Capital, Inc.

image2

  • Experienced medical and business development professional with broad skills across a wide range of areas, from diagnostics, medical informatics and medical device development to improved care delivery systems. 
  • Enable Biosciences, CEO, co-founded with two multi-award-winning Stanford / UC Berkeley Ph.D. candidates is developing a patent-pending, rapid, multiplexable antibody detection platform technology that is 1000 times more sensitive than any others. The platform promises to revolutionize early diagnosis and precision monitoring of challenging antibody-associated diseases. This logarithmic-leap technology will greatly facilitate timely and targeted therapeutic intervention for better patient outcomes. The startup, under its pre-incorporation name of Samba Biosciences, was selected to participate in the 2015 Summer UCSF Lean Launchpad for Health Sciences program and graduated as a top-rated team. The team was also featured as a Startup Showcase in the 2015 Harvard Business School Entrepreneurship Summit, held April 28, 2015. On March 3, 2016, Enable Biosciences won the Bay Area-Northwestern Regional Harvard Business School New Venture Competition, voted into first place by a panel of top VC judges out of 27 highly competitive teams. 
  • I maintain an active part-time medical practice that keeps me connected to patients and clinical opportunities while providing a rich direct environment for market-research testing.

David Seftel, MD, LinkedIn 

Enable Biosciences

Will Robberts, CEO TesoRx

image3

  • Will is the Co-Founder and President of TesoRx Pharma. The company is developing the first pure oral Testosterone treatment in the market for treating male hypogonadism. 
  • His career started with KPMG in South Africa from where he moved to the London Corporate Finance team and advised on a number of landmark transactions in the technology, communications and entertainment sectors.  
  • Since moving to the United States in 2000 he has held C-suite positions where he has facilitated a number of successful exits. Will is a Chartered Accountant with a Bachelor of Commerce degree, an Honors degree in Accounting as well as a Masters degree in Financial Management and Economics. 
  • Will is on the board of TesoRx Pharma LLC, LIPAC Oncology LLC, Enable Biosciences, Inc., SmartDepo, Inc., Kempton Investments LLC  

Will Robberts, LinkedIn

TesoRX Pharmaceuticals


Mark Stoner, CEO, Life Sciences Capital, Inc.

image4

  • Senior business development leader with US and international experience for firms including Accenture, PriceWaterhouseCoopers, and other leading tech companies. 
  • Exceeded $30 million annual quota at Accenture. Other roles included France Telecom in Paris and RVP for national mortgage banker. 
  • Most recently, Global Alliance Development Director, for Applicature. Applicature is a Blockchain development agency and has done 20 ICO’s that have raised over $200 million.  Recruited and managed a sales team. 
  • VP of Business Development for a British Government economic development agency. Registered lobbyist with the US Dept. of Justice to represent the United Kingdom in the US. Sold the value of foreign direct investment with multinational clients. Lead key account relationships to establish manufacturing facilities, call centers, supply chain partners, biotech, and research facilities creating jobs in the UK. 

Mark Stoner, LinkedIn

Applicature